North China Pharmaceutical Company.Ltd Balance Sheet Health
Financial Health criteria checks 1/6
North China Pharmaceutical Company.Ltd has a total shareholder equity of CN¥6.6B and total debt of CN¥11.4B, which brings its debt-to-equity ratio to 172.4%. Its total assets and total liabilities are CN¥21.7B and CN¥15.1B respectively. North China Pharmaceutical Company.Ltd's EBIT is CN¥583.1M making its interest coverage ratio 1.5. It has cash and short-term investments of CN¥1.7B.
Key information
172.4%
Debt to equity ratio
CN¥11.39b
Debt
| Interest coverage ratio | 1.5x |
| Cash | CN¥1.72b |
| Equity | CN¥6.61b |
| Total liabilities | CN¥15.10b |
| Total assets | CN¥21.71b |
Recent financial health updates
No updates
Recent updates
Benign Growth For North China Pharmaceutical Company.Ltd (SHSE:600812) Underpins Its Share Price
Sep 25
North China Pharmaceutical Company.Ltd's (SHSE:600812) Profits Appear To Have Quality Issues
Aug 20The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet
Apr 26Financial Position Analysis
Short Term Liabilities: 600812's short term assets (CN¥8.7B) do not cover its short term liabilities (CN¥11.1B).
Long Term Liabilities: 600812's short term assets (CN¥8.7B) exceed its long term liabilities (CN¥4.0B).
Debt to Equity History and Analysis
Debt Level: 600812's net debt to equity ratio (146.4%) is considered high.
Reducing Debt: 600812's debt to equity ratio has increased from 159.3% to 172.4% over the past 5 years.
Debt Coverage: 600812's debt is not well covered by operating cash flow (13.1%).
Interest Coverage: 600812's interest payments on its debt are not well covered by EBIT (1.5x coverage).